# Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

> **NCT06168214** · PHASE4 · RECRUITING · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 1404 (estimated)

## Conditions studied

- the Eradication Rates of Helicobacter Pylori

## Interventions

- **DRUG:** Rabeprazloe+bismuth+amoxicillin+clarithromycin
- **DRUG:** Vonoprazan+amoxicillin+clarithromycin 14 days
- **DRUG:** Vonoprazan+amoxicillin+clarithromycin 7 days
- **DRUG:** Vonoprazan+tetracycline+furazolidone 14 days
- **DRUG:** Vonoprazan+tetracycline+furazolidone 7 days
- **DRUG:** Vonoprazan+amoxicillin+furazolidone 7 days
- **DRUG:** Vonoprazan+amoxicillin+tetracycline 14 days
- **DRUG:** Vonoprazan+amoxicillin 7 days
- **DRUG:** Vonoprazan+amoxicillin 14 days

## Key facts

- **NCT ID:** NCT06168214
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-04
- **Primary completion:** 2024-11-25
- **Final completion:** 2024-12-25
- **Target enrollment:** 1404 (ESTIMATED)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168214, "Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06168214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*